| Product Code: ETC7135486 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Estonia saw significant import shipments of large molecule drug substances from Lithuania, Finland, Germany, Sweden, and Poland, with a high Herfindahl-Hirschman Index (HHI) indicating market concentration. The compound annual growth rate (CAGR) from 2020 to 2024 stood at a robust 16.41%, showcasing a thriving market. The growth rate from 2023 to 2024 was also strong at 8.53%, reflecting sustained momentum in the importation of these critical pharmaceutical components. Estonia`s reliance on these key exporting countries underscores the importance of international partnerships in meeting its pharmaceutical needs.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Estonia Large Molecule Drug Substance CDMO Market Overview |
3.1 Estonia Country Macro Economic Indicators |
3.2 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Estonia Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Estonia Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Estonia Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for biologics and large molecule drugs globally |
4.2.2 Growing trend of outsourcing drug substance manufacturing to specialized CDMOs |
4.2.3 Technological advancements in large molecule drug development and manufacturing |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for large molecule drug manufacturing |
4.3.2 High initial investment and infrastructure costs for establishing large molecule drug manufacturing facilities |
5 Estonia Large Molecule Drug Substance CDMO Market Trends |
6 Estonia Large Molecule Drug Substance CDMO Market, By Types |
6.1 Estonia Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Estonia Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Estonia Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Estonia Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Estonia Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Estonia Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Estonia Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Estonia Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Percentage of revenue allocated to research and development in large molecule drug substance CDMO market |
8.2 Number of strategic partnerships and collaborations formed by Estonian companies in the large molecule drug substance CDMO space |
8.3 Average time to market for large molecule drug substance products developed by Estonian CDMOs |
9 Estonia Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Estonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Estonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Estonia Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Estonia Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Estonia Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Estonia Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |